FOLH1 and metastatic prostate carcinoma: 177Lu-PSMA radionuclide therapy (up to a maximum of 6 rounds of therapy) or cabazitaxel chemotherapy was administered randomly to 200 individuals with metastatic prostate cancer who progressed after hormonal therapy and first-line chemotherapy (up to a maximum of 10 cycles of therapy), and the severity of adverse events was examined in this trial [[174], [175], [176]].